Palatin Technologies, Inc
Palatin Technologies is dedicated to discovering and developing novel therapeutics for patients with inflammatory and autoimmune conditions, leveraging their expertise in the melanocortin system to create treatments that resolve harmful inflammation and promote healing.
Industries
Nr. of Employees
small (1-50)
Palatin Technologies, Inc
4-B Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, NJ 08512
Patents
Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy
US-11286280-B2
View Details
Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy
US-11286280-B2
View DetailsProducts
Bremelanotide (approved injectable therapy)
An approved injectable therapy for a specified female sexual dysfunction indication (generalized hypoactive sexual desire disorder); developed and brought to regulatory approval and commercialization.
PL9643 (ophthalmology development candidate)
A clinical-stage therapeutic candidate (melanocortin receptor agonist) under development for dry eye disease; advanced to Phase 3 clinical study.
Bremelanotide (approved injectable therapy)
An approved injectable therapy for a specified female sexual dysfunction indication (generalized hypoactive sexual desire disorder); developed and brought to regulatory approval and commercialization.
PL9643 (ophthalmology development candidate)
A clinical-stage therapeutic candidate (melanocortin receptor agonist) under development for dry eye disease; advanced to Phase 3 clinical study.
Services
Establishing partnerships and strategic alliances for therapeutic development and commercialization, including collaboration on development programs and licensing.
Establishing partnerships and strategic alliances for therapeutic development and commercialization, including collaboration on development programs and licensing.
Expertise Areas
- Clinical trial management
- Inflammation and immunology therapeutics
- Ophthalmology drug development
- Chemistry, Manufacturing and Controls (CMC)
Key Technologies
- Melanocortin receptor-targeted therapeutics
- Injectable drug formulation
- CMC and CDMO/CMO management
- Phase 2/Phase 3 clinical trial execution